TUESDAY, Feb 5 (HealthDay News) -- The drug Byetta, approved for
adults with type 2 diabetes, appears to help severely obese teens
lose some weight, a small study found.
Researchers assigned 26 teens, ages 12 to 19, either to
injections of Byetta (exenatide) or placebo injections twice daily.
After three months, those who got the drug had a nearly 3 percent
greater reduction in their body mass index (BMI, a measure of
height versus weight) compared to those on placebo.
However, that difference remains "modest," said researcher Aaron
Kelly, assistant professor of pediatrics at the University of
Minnesota Medical School and Amplatz Children's Hospital.
"We are not proposing this be prescribed clinically," he said. The study was small, only lasted six months and more study is needed, he added.
According to Kelly, Byetta may only be another tool to help the
4 percent to 6 percent of U.S. children and teens who are severely
obese. "It's ultimately going to take more than one medication," he
said. "It's going to take combinations of medication."
The new research was published online Feb. 4 in
While some research suggests that the levels of obesity,
overall, in children and teens may be leveling off, "we think
severe obesity is the fastest growing subcategory," Kelly noted. A
BMI of 35 or more is considered severely obese. An example would be
a teenage boy of average height who weighs 220 pounds, experts
Children like these may begin to face serious health risks.
"Severe obesity, even in children, is associated with an increased
risk for cardiovascular disease and diabetes," Kelly said.
Typically, lifestyle advice to exercise more and reduce portion
sizes has not worked well in teens who are severely obese, he
His team decided to look at Byetta because it has been shown to
reduce body weight in adults with type 2 diabetes. In adults, the
drug is often used when other drugs fail to control diabetes, he
Byetta works by helping to reduce blood sugar levels after
meals, Kelly explained. It is thought to help reduce weight, he
said, by acting on receptors in the brain that control appetite and
by increasing feelings of fullness after eating.
All the teens in the study got instructions for lifestyle
changes aimed at losing weight. Half of the teens got the injected
drug twice a day, before breakfast and before dinner. The others
were injected with what looked like an identical drug, but was in
fact a placebo.
In all, 22 of the 26 children initially enrolled finished the
first three months of the study. At that time, those on the drug
lost about seven more pounds on average than those on placebo.
After the three months, those on the placebo had the option of
taking Byetta. At the end of six months, those on the drug for the
entire study had lost an average of 4 percent more, in terms of
their BMI, compared to the others.
One expert agreed that the added weight loss was modest.
"As has been shown in adults, exenatide does appear to produce some weight loss," said Dr. Jeffrey Schwimmer, professor of pediatrics at the University of California, San Diego.
Schwimmer, who also wrote an editorial accompanying the study,
said that "there is likely to be variability in who does and
doesn't respond [to Byetta]." One challenge for researchers, as
more drugs become available, he said, is to predict which teens
will best respond to these medicines.
According to the study, the most common side effects were
gastrointestinal, such as nausea and vomiting, but these effects
resolved over time.
The study ended at six months, so Kelly doesn't know if the
teens kept off the weight long-term.
While the weight loss differences were modest, Kelly said those
on the drug also showed a slight, healthy decrease in systolic
blood pressure (the upper number of the reading), which is
important to reduce heart risk factors.
Still, there's the drug's price to consider, as well: A month's
supply costs $350 or more, Kelly said.
He said his team plans to study other medications in the same
class of drugs, and combinations of drugs, to see if they can
produce better results. Recently, the Food and Drug Administration
approved two new drugs for the treatment of obesity in adults,
Belviq and Qsymia.
The study was funded by the University of Minnesota, the
National Center for Research Resources and the National Institutes
of Health. Kelly has received research funding from Amylin, which
To learn more about childhood obesity, visit the
U.S. Centers for Disease Control and
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.